• Publications
  • Influence
MNX1‐AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma
Motor neuron and pancreas homeobox 1‐antisense RNA1 (MNX1‐AS1) is a novel long noncoding RNA and has been suggested to be overexpressed in human ovarian cancer and glioma. The role of MNX1‐AS1 inExpand
  • 8
  • 1
Identification of SPP1 as a promising biomarker to predict clinical outcome of lung adenocarcinoma individuals.
We identified and investigated the prognostic value of secreted phosphoprotein 1 (SPP1) in lung adenocarcinoma (LUAD) patients and evaluate the relationship between the SPP1 expression level andExpand
  • 16
Discovery of potent pyruvate dehydrogenase kinase inhibitors and evaluation of their anti-lung cancer activity under hypoxia.
Targeting pyruvate dehydrogenase kinases (PDKs) reverses the Warburg effect, which could be a potential therapeutic target for anti-cancer drug discovery. In this paper, we identified 12 potentialExpand
  • 5
Cardiac P2X4 Receptors
### Purinergic receptors have attracted growing interest as therapeutic targets. This perspective focuses on P2X4 receptors as a new cardioprotective target in heart failure. Purinergic1 receptorsExpand
  • 3
Epidermal Stem Cells in Wound Healing and Regeneration
Skin stem cells distributed in the basal layer of the epidermis and hair follicles are important cell sources for skin development, metabolism, and injury repair. At present, great progress has beenExpand
  • 1
  • PDF
Left upper lobectomy and pulmonary angioplasty by uniportal video-assisted thoracic surgery.
Diego Gonzalez-Rivas and his colleagues performed the first case for pulmonary major resection by the uniportal approach in 2010. In the following years, more and more expert surgeons developed theExpand
  • 1
A facile adenosine triphosphate-responsive nanoplatform for efficacious therapy of esophageal cancer
Current chemotherapeutic agents against esophageal cancer (EC) are suboptimal. To improve treatment efficacy, a nanoplatform based on ATP-responsive drug release was developed for EC therapy. First,Expand